{
  "meta": {
    "title": "00027_Mid_Day_Module_Medicine-10",
    "url": "https://brainandscalpel.vercel.app/00027-mid-day-module-medicine-10-a60da1b1.html",
    "scrapedAt": "2025-11-29T18:11:57.722Z"
  },
  "questions": [
    {
      "id": 53944,
      "choices": [
        {
          "id": 215245,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Alpha-1 antitrypsin (AAT) level measurement</span></span></p>"
        },
        {
          "id": 215246,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Chest X-ray</span></span></p>"
        },
        {
          "id": 215247,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">High-resolution computed tomography (HRCT) scan of the chest</span></span></p>"
        },
        {
          "id": 215248,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Genetic testing for cystic fibrosis</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 40-year-old male presents with a family history of early-onset emphysema. Pulmonary function tests reveal airflow obstruction that does not improve significantly with bronchodilators. What is the most appropriate initial diagnostic test?</span></span></span></p>",
      "unique_key": "Q1491669",
      "question_audio": null,
      "question_video": null,
      "map_id": 16556477,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">A) Alpha-1 antitrypsin (AAT) level measurement</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Measurement of alpha-1 antitrypsin (AAT) levels is the most appropriate initial diagnostic test for suspected AAT deficiency. Low serum levels of AAT confirm the diagnosis, particularly in individuals with a family history of early-onset emphysema.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Chest X-ray</span></strong><span style=\"font-size:12.0pt\">: While chest X-ray may reveal findings suggestive of emphysema, it is not specific for AAT deficiency and may not establish a definitive diagnosis.</span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. High-resolution computed tomography (HRCT) scan of the chest</span></strong><span style=\"font-size:12.0pt\">: HRCT may show characteristic changes of emphysema, but it is not specific for AAT deficiency and may not be necessary as an initial diagnostic test.</span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Genetic testing for cystic fibrosis</span></strong><span style=\"font-size:12.0pt\">: Genetic testing for cystic fibrosis is not indicated in the absence of clinical features suggestive of the condition, such as pancreatic insufficiency and elevated sweat chloride levels.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Alpha-1 antitrypsin (AAT) level measurement is the initial diagnostic test for suspected AAT deficiency helps in establishing a timely and accurate diagnosis to guide management decisions.</span></span></span></p>",
      "correct_choice_id": 215245,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53947,
      "choices": [
        {
          "id": 215257,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Wilson Disease</span></span></p>"
        },
        {
          "id": 215258,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hemochromatosis</span></span></p>"
        },
        {
          "id": 215259,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Alpha1 antitrypsin (A1AT) deficiency</span></span></p>"
        },
        {
          "id": 215260,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Systemic lupus erythematosus (SLE)</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 45-year-old male presents with fatigue, weakness, and joint pain. Physical examination reveals skin pigmentation as in the image below and hepatomegaly. Laboratory tests show elevated serum ferritin levels and increased transferrin saturation. What is the most likely diagnosis?</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/14/screenshot-2024-08-14-180615.jpg\" style=\"height:205px; width:300px\" /></span></span></span></p>",
      "unique_key": "Q8719056",
      "question_audio": null,
      "question_video": null,
      "map_id": 16556478,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">B) Hemochromatosis</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The presentation of fatigue, weakness, joint pain, bronze skin pigmentation, hepatomegaly, elevated serum ferritin levels, and increased transferrin saturation is highly suggestive of hemochromatosis. Hemochromatosis is a genetic disorder characterized by excessive absorption and accumulation of iron in various organs, leading to their dysfunction.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A.</span></strong><span style=\"font-size:12.0pt\"> Wilson Disease involves copper accumulation and typically presents with liver dysfunction and neuropsychiatric symptoms, not primarily iron overload symptoms.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.</span></strong><span style=\"font-size:12.0pt\"> Alpha1 antitrypsin (A1AT) deficiency is a genetic disorder that can lead to liver disease and lung disease, but it is not associated with iron overload or the specific constellation of symptoms described.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D.</span></strong><span style=\"font-size:12.0pt\"> Systemic lupus erythematosus (SLE) is an autoimmune disease that can affect multiple organ systems and cause a wide range of symptoms, but it does not cause iron overload or the specific features described here.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The clinical features of hemochromatosis, includes fatigue, bronze skin pigmentation, hepatomegaly, and elevated serum ferritin levels.</span></span></span></p>",
      "correct_choice_id": 215258,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "ImageBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20275,
      "choices": [
        {
          "id": 81061,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Serum albumin level</span></span></span></p>"
        },
        {
          "id": 81062,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">International normalized ratio (INR)</span></span></span></p>"
        },
        {
          "id": 81063,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Serum sodium level</span></span></span></p>"
        },
        {
          "id": 81064,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ascites</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following parameters is NOT included in the Child-Turcotte-Pugh (CTP) score to assess the severity of liver disease?</span></span></p>",
      "unique_key": "Q5557465",
      "question_audio": null,
      "question_video": null,
      "map_id": 16556479,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Serum sodium level</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The CTP score assesses the severity of liver cirrhosis using five clinical and laboratory parameters: serum bilirubin, serum albumin, INR, ascites, and hepatic encephalopathy. Serum sodium level is not included in the CTP score but is considered in the Model for End-Stage Liver Disease (MELD) score.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Serum albumin level:</span></strong><span style=\"font-size:12.0pt\"> Is included in the CTP score as a measure of the liver&#39;s synthetic function.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. International normalized ratio:</span></strong><span style=\"font-size:12.0pt\"> INR is included to assess the liver&#39;s ability to synthesize clotting factors.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Ascites:</span></strong><span style=\"font-size:12.0pt\"> The presence and severity of ascites are used to evaluate the liver&#39;s synthetic function and portal hypertension.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">To recognize the components of the Child-Turcotte-Pugh score and understand that serum sodium level is not included in this assessment of liver disease severity.</span></span></span></p>",
      "correct_choice_id": 81063,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "CriteriaBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20280,
      "choices": [
        {
          "id": 81081,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Budd-Chiari syndrome </span></span></span></p>"
        },
        {
          "id": 81082,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Congestive heart failure </span></span></span></p>"
        },
        {
          "id": 81083,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Malignant ascites </span></span></span></p>"
        },
        {
          "id": 81084,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hepatic venous outflow obstruction</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 45-year-old female with no significant medical history presents with abdominal swelling and discomfort. A diagnostic paracentesis shows a SAAG of 0.9 g/dL. Which of the following conditions is most likely associated with her ascites? </span></span></span></p>",
      "unique_key": "Q5824983",
      "question_audio": null,
      "question_video": null,
      "map_id": 16556480,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. </span></strong><strong><span style=\"font-size:12.0pt\">C) Malignant ascites</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A serum-ascites albumin gradient (SAAG) lower than 1.1 g/dL suggests that the ascites is not due to portal hypertension. In this case, the most likely cause of ascites with a SAAG of 0.9 g/dL is malignant ascites, which is caused by the direct spread of malignancy in the peritoneal cavity, leading to fluid accumulation due to cancer-related inflammation and changes in vascular permeability.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Options A. Budd-Chiari syndrome and D. Hepatic venous outflow obstruction</span></strong><span style=\"font-size:12.0pt\">: Both typically lead to portal hypertension and would more likely present with a SAAG greater than 1.1 g/dL.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Congestive heart failure:</span></strong><span style=\"font-size:12.0pt\"> Can cause ascites due to increased hydrostatic pressure in the systemic and portal venous systems, typically resulting in a SAAG greater than 1.1 g/dL, indicating that the ascites is due to portal hypertension secondary to heart failure.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A SAAG lower than 1.1 g/dL suggests the ascites is not due to portal hypertension and that malignant ascites is caused by the direct spread of cancer in the peritoneal cavity.</span></span></span></p>",
      "correct_choice_id": 81083,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20282,
      "choices": [
        {
          "id": 81089,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Increase the dose of his current diuretic</span></span></span></p>"
        },
        {
          "id": 81090,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Start antibiotic prophylaxis</span></span></span></p>"
        },
        {
          "id": 81091,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Perform a large-volume paracentesis</span></span></span></p>"
        },
        {
          "id": 81092,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Restrict dietary sodium</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 55-year-old man with a history of cirrhosis due to chronic hepatitis C infection presents with new-onset ascites. What is the most appropriate initial step in the management of his ascites?</span></span></p>",
      "unique_key": "Q5348893",
      "question_audio": null,
      "question_video": null,
      "map_id": 16556481,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Restrict dietary sodium</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Dietary sodium restriction is a cornerstone in the initial management of ascites, particularly in cirrhotic patients, to help reduce fluid accumulation. This approach, often in conjunction with diuretic therapy, aims to decrease sodium and water retention.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Increase the dose of his current diuretic:</span></strong><span style=\"font-size:12.0pt\"> Increasing the dose of his current diuretic without first attempting dietary modifications may lead to electrolyte imbalances and kidney injury.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Start antibiotic prophylaxis:</span></strong><span style=\"font-size:12.0pt\"> Antibiotic prophylaxis is indicated in specific situations, such as prior episodes of spontaneous bacterial peritonitis (SBP), but not as an initial step for all cases of ascites.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Perform a large-volume paracentesis:</span></strong><span style=\"font-size:12.0pt\">&nbsp; Large-volume paracentesis is typically reserved for tense ascites causing respiratory discomfort or as a diagnostic procedure.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Dietary sodium restriction is the initial management strategy for patients with cirrhosis presenting with ascites.</span></span></span></p>",
      "correct_choice_id": 81092,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20286,
      "choices": [
        {
          "id": 81105,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Child-Pugh class A</span></span></span></p>"
        },
        {
          "id": 81106,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Child-Pugh class B</span></span></span></p>"
        },
        {
          "id": 81107,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Child-Pugh class C</span></span></span></p>"
        },
        {
          "id": 81108,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Child-Pugh class D</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Child-Pugh score of 8 comes under ?</span></span></p>",
      "unique_key": "Q3876863",
      "question_audio": null,
      "question_video": null,
      "map_id": 16556482,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B. Child-Pugh class B</span></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The Child-Pugh score is calculated by adding the scores for the five factors and can range from 5 to 15. The resulting Child-Pugh class can be A (a score of 5&ndash;6), B (7&ndash;9), or C (&ge;10). Decompensation indicates cirrhosis, with a Child-Pugh score of &ge;7 (class B).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ref: Harrison&rsquo;s 21<sup>st</sup> edition page no 2552</span></strong></span></span></p>",
      "correct_choice_id": 81106,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20288,
      "choices": [
        {
          "id": 81113,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Start systemic corticosteroids </span></span></span></p>"
        },
        {
          "id": 81114,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Prescribe a long-acting muscarinic antagonist </span></span></span></p>"
        },
        {
          "id": 81115,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Initiate antibiotic therapy </span></span></span></p>"
        },
        {
          "id": 81116,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Increase the dose of the short-acting bronchodilator</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 72-year-old woman with a history of chronic obstructive pulmonary disease (COPD) presents to the clinic with increased shortness of breath, wheezing, and productive cough for the past 2 days. She uses a short-acting bronchodilator as needed. Which of the following is the most appropriate initial treatment? </span></span></p>",
      "unique_key": "Q8535194",
      "question_audio": null,
      "question_video": null,
      "map_id": 16556483,
      "difficulty_level": "difficult",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. </span></strong><strong><span style=\"font-size:12.0pt\">A) Start systemic corticosteroids</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In a patient with COPD presenting with an acute exacerbation characterized by increased shortness of breath, wheezing, and a change in sputum production or color, the initiation of systemic corticosteroids is an appropriate initial treatment. Corticosteroids help to reduce airway inflammation and improve symptoms in acute exacerbations of COPD.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">&nbsp;<u>Explanation:</u></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Prescribing a long-acting muscarinic antagonist:</span></strong><span style=\"font-size:12.0pt\"> Prescribing a long-acting muscarinic antagonist (LAMA) is a good option for long-term management of COPD to improve symptoms and reduce exacerbations, but it is not the first choice for treating an acute exacerbation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Initiate antibiotic therapy:</span></strong><span style=\"font-size:12.0pt\"> Antibiotic therapy may be indicated if there is a strong suspicion or evidence of a bacterial infection contributing to the exacerbation, such as increased sputum purulence, but it is not the standard initial treatment for all acute COPD exacerbations.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Increase the dose of the short-acting bronchodilator:</span></strong><span style=\"font-size:12.0pt\">&nbsp; Increasing the dose of a short-acting bronchodilator can provide symptomatic relief and is often part of the management of acute exacerbations, but it may not be sufficient on its own without addressing the inflammation with corticosteroids.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Systemic corticosteroids are an appropriate initial treatment for an acute exacerbation of COPD, as they address the underlying airway inflammation and can improve symptoms and lung function.</span></span></span></p>",
      "correct_choice_id": 81113,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20291,
      "choices": [
        {
          "id": 81125,
          "text": "<p><span style=\"font-size:12.0pt;\">Acute stroke</span></p>"
        },
        {
          "id": 81126,
          "text": "<p><span style=\"font-size:12.0pt;\">Hepatic encephalopathy</span></p>"
        },
        {
          "id": 81127,
          "text": "<p><span style=\"font-size:12.0pt;\">Alzheimer's disease</span></p>"
        },
        {
          "id": 81128,
          "text": "<p><span style=\"font-size:12.0pt;\">Normal pressure hydrocephalus</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 62-year-old man with a history of cirrhosis due to chronic hepatitis B infection presents with altered mental status. On examination, he exhibits asterixis. Which of the following best describes this patient's condition?</span></p>",
      "unique_key": "Q4966915",
      "question_audio": null,
      "question_video": null,
      "map_id": 16556484,
      "difficulty_level": "difficult",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. B) Hepatic encephalopathy</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option B:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">The presentation of altered mental status, increasing confusion, difficulty performing simple tasks, and the presence of asterixis (a flapping tremor of the hands when the wrists are extended) in a patient with a history of cirrhosis due to chronic hepatitis B infection is most consistent with hepatic encephalopathy. Hepatic encephalopathy is a neuropsychiatric syndrome caused by liver dysfunction and the inability to detoxify substances, leading to the accumulation of toxins such as ammonia, which affects brain function.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong><u>Explanation:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option A. Acute stroke:</strong> Typically presents with sudden onset neurological deficits such as weakness or numbness on one side of the body, difficulty speaking, or facial drooping, which are not described in this case.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C. Alzheimer's disease:</strong> Is a progressive neurodegenerative disorder characterized by gradual memory loss, cognitive decline, and changes in behavior, but it does not typically present with acute changes or asterixis.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D. Normal pressure hydrocephalus:</strong> Is characterized by the triad of gait disturbance, urinary incontinence, and cognitive decline, but the acute onset and presence of asterixis are more indicative of hepatic encephalopathy in the context of known liver disease.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong><u>Educational Objective:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Hepatic encephalopathy's characteristic presentation in a patient with underlying liver disease, includes altered mental status, confusion, difficulty with tasks, and asterixis, which highlights liver function in neuropsychiatric status.</span></p>",
      "correct_choice_id": 81126,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20299,
      "choices": [
        {
          "id": 81157,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Oral lactulose</span></span></span></p>"
        },
        {
          "id": 81158,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Intravenous albumin</span></span></span></p>"
        },
        {
          "id": 81159,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Oral propranolol</span></span></span></p>"
        },
        {
          "id": 81160,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">High-dose vitamin K</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is the most appropriate long-term treatment to prevent further episodes of hepatic encephalopathy in a patient with advanced cirrhosis?</span></span></p>",
      "unique_key": "Q4199557",
      "question_audio": null,
      "question_video": null,
      "map_id": 16556485,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Oral lactulose</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Oral lactulose is the most appropriate long-term treatment for preventing recurrent episodes of hepatic encephalopathy in a patient with advanced cirrhosis. Lactulose is a non-absorbable disaccharide that works by acidifying the colonic contents, leading to the conversion of ammonia to ammonium, which is not absorbed, thereby reducing blood ammonia levels and preventing episodes of hepatic encephalopathy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Intravenous albumin:</span></strong><span style=\"font-size:12.0pt\"> Intravenous albumin is used in the management of patients with cirrhosis and complications such as spontaneous bacterial peritonitis or hepatorenal syndrome, but it is not a standard treatment for preventing hepatic encephalopathy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Oral propranolol:</span></strong><span style=\"font-size:12.0pt\"> Oral propranolol is used for primary prophylaxis of variceal bleeding in cirrhotic patients by reducing portal hypertension, not for preventing hepatic encephalopathy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. High-dose vitamin K:</span></strong><span style=\"font-size:12.0pt\"> High-dose vitamin K is sometimes used in cirrhotic patients to correct coagulopathy, but it does not play a role in the prevention of hepatic encephalopathy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Oral lactulose is the most appropriate long-term treatment for preventing recurrent episodes of hepatic encephalopathy in patients with advanced cirrhosis, due to its mechanism of reducing blood ammonia levels.</span></span></span></p>",
      "correct_choice_id": 81157,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20301,
      "choices": [
        {
          "id": 81165,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"IT\" style=\"font-size:12.0pt\">Hypoglycemia</span></span></span></p>"
        },
        {
          "id": 81166,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"IT\" style=\"font-size:12.0pt\">Elevated alpha-fetoprotein (AFP)</span></span></span></p>"
        },
        {
          "id": 81167,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"IT\" style=\"font-size:12.0pt\">Hyponatremia</span></span></span></p>"
        },
        {
          "id": 81168,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"IT\" style=\"font-size:12.0pt\">Hypoalbuminemia</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 62-year-old woman with a history of non-alcoholic steatohepatitis (NASH) presents with worsening fatigue and abdominal distension. An abdominal ultrasound reveals a nodular liver and ascites. Which additional finding would most suggest the presence of hepatocellular carcinoma (HCC)?</span></span></p>",
      "unique_key": "Q2944307",
      "question_audio": null,
      "question_video": null,
      "map_id": 16556486,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Elevated alpha-fetoprotein (AFP)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Elevated alpha-fetoprotein (AFP) is a tumor marker often associated with hepatocellular carcinoma (HCC). In the context of a patient with risk factors for liver cancer, such as non-alcoholic steatohepatitis (NASH) and findings suggestive of cirrhosis (nodular liver and ascites), an elevated AFP would further suggest the presence of HCC.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Hypoglycemia:</span></strong><span style=\"font-size:12.0pt\"> Hypoglycemia can occur in advanced liver disease due to the liver&#39;s impaired gluconeogenesis, but it is not specific for HCC.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Hyponatremia:</span></strong><span style=\"font-size:12.0pt\"> Hyponatremia is common in advanced liver disease, particularly with the development of ascites and portal hypertension, but it is not specific for HCC.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Hypoalbuminemia:</span></strong><span style=\"font-size:12.0pt\"> Hypoalbuminemia is indicative of liver dysfunction and is a common feature of cirrhosis and advanced liver disease but does not specifically suggest HCC.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">An elevated alpha-fetoprotein (AFP) level, particularly in a patient with risk factors and liver disease such as NASH, is suggestive of hepatocellular carcinoma (HCC).</span></span></span></p>",
      "correct_choice_id": 81166,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19805,
      "choices": [
        {
          "id": 79181,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">It promotes cell growth and division </span></span></span></p>"
        },
        {
          "id": 79182,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">It controls proto-oncogene activity </span></span></span></p>"
        },
        {
          "id": 79183,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">It induces angiogenesis </span></span></span></p>"
        },
        {
          "id": 79184,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">It evades apoptosis</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 45-year-old woman presents with a family history of breast and ovarian cancer. Genetic testing reveals a germline mutation in a gene that normally functions to inhibit cell cycle progression and repair DNA damage. Which of the following best describes the role of the affected gene in this patient&#39;s cancer predisposition?</span></span></span></p>",
      "unique_key": "Q3996333",
      "question_audio": null,
      "question_video": null,
      "map_id": 16556487,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>B) It controls proto-oncogene activity</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The clinical vignette describes a patient with a likely germline mutation in a tumor suppressor gene, such as BRCA1 or BRCA2. Tumor suppressor genes normally function to regulate cell growth and division, often by inhibiting proto-oncogene activity or promoting DNA repair. Loss of function of these genes, due to inherited or acquired mutations, removes the critical checks on cell growth and can lead to cancer development. &nbsp; </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Promote cell growth and division:</span></strong><span style=\"font-size:12.0pt\"> This is the opposite of what tumor suppressor genes do. They actually inhibit cell growth and division, acting as a brake on the cell cycle.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Induce angiogenesis:</span></strong><span style=\"font-size:12.0pt\"> Angiogenesis (the formation of new blood vessels) is often promoted by cancer cells, not suppressed. Tumor suppressor genes may indirectly inhibit angiogenesis by preventing uncontrolled cell growth.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Evade apoptosis:</span></strong><span style=\"font-size:12.0pt\"> Apoptosis (programmed cell death) is a crucial process for eliminating damaged or abnormal cells. Tumor suppressor genes often promote apoptosis, not evade it.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The primary function of tumor suppressor genes is to control proto-oncogene activity, thereby preventing uncontrolled cell growth and maintaining genomic stability. Inherited mutations in tumor suppressor genes can significantly increase an individual&#39;s risk of developing certain types of cancer. </span></span></span></p>",
      "correct_choice_id": 79182,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19806,
      "choices": [
        {
          "id": 79185,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ivosidenib</span></span></span></p>"
        },
        {
          "id": 79186,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Romidepsin</span></span></span></p>"
        },
        {
          "id": 79187,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Panobinostat</span></span></span></p>"
        },
        {
          "id": 79188,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Belinostat</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 56-year-old man presents to his primary care physician with a 3-month history of worsening fatigue and unintentional weight loss. His past medical history is significant for hypertension and type 2 diabetes, both well-controlled with medications. He has a 30-pack-year smoking history but quit 10 years ago. Physical examination reveals pallor and generalized lymphadenopathy. Laboratory studies show anemia and thrombocytopenia. A peripheral blood smear demonstrates blast cells. A bone marrow biopsy is performed, and the pathology report indicates acute myeloid leukemia (AML) with a specific chromosomal translocation. Further molecular studies reveal a mutation leading to increased activity of histone deacetylases (HDACs), which is known to be associated with a poor prognosis in this type of leukemia. The oncologist discusses treatment options with the patient, focusing on the potential use of HDAC inhibitors as part of his chemotherapy regimen. Which of the following is not a HDAC inhibitor?</span></span></span></p>",
      "unique_key": "Q9940626",
      "question_audio": null,
      "question_video": null,
      "map_id": 16556488,
      "difficulty_level": "difficult",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>A) Ivosidenib</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ivosidenib is not a histone deacetylase (HDAC) inhibitor. It is actually an inhibitor of the isocitrate dehydrogenase 1 (IDH1) enzyme, which is a different target used in the treatment of certain types of leukemia, particularly those with IDH1 mutations.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B) Romidepsin, C)&nbsp; panobinostat, and D) belinostat</span></strong><span style=\"font-size:12.0pt\"> are all examples of HDAC inhibitors. These drugs work by inhibiting histone deacetylases, which are enzymes involved in the epigenetic regulation of gene expression. By inhibiting these enzymes, HDAC inhibitors can induce cell cycle arrest, differentiation, and apoptosis of cancer cells, making them useful in the treatment of certain hematologic malignancies and solid tumors.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">HDAC inhibitors, such as romidepsin, panobinostat, and belinostat, are used in cancer therapy to inhibit histone deacetylases, leading to epigenetic modulation of gene expression and inducing apoptosis in cancer cells. Ivosidenib, on the other hand, is an IDH1 inhibitor used in the treatment of cancers with IDH1 mutations.</span></span></span></p>",
      "correct_choice_id": 79185,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19749,
      "choices": [
        {
          "id": 78957,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Proto-oncogenes causes cancer by gain of function mutations, while tumor suppressor genes cause cancer due to loss of function mutations.</span></span></p>"
        },
        {
          "id": 78958,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Proto-oncogenes are typically inactivated in cancer, while tumor suppressor genes are overactivated.</span></span></p>"
        },
        {
          "id": 78959,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Proto-oncogenes are exclusively found in malignant tumors, while tumor suppressor genes are found in benign tumors.</span></span></p>"
        },
        {
          "id": 78960,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Proto-oncogenes encode for growth factors, while tumor suppressor genes encode for growth factor receptors.</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In the context of cancer development, which of the following statements best differentiates proto-oncogenes from tumor suppressor genes?</span></span></p>",
      "unique_key": "Q1570683",
      "question_audio": null,
      "question_video": null,
      "map_id": 16556489,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">A) Proto-oncogenes cause cancer by gain of function mutations, while tumor suppressor genes cause cancer due to loss of function mutations.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Proto-oncogenes are normal genes that, when mutated or overexpressed, become oncogenes that can contribute to cancer development. These mutations often result in a gain of function, leading to increased cell growth and proliferation. Examples include the RAS and MYC genes.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Tumor suppressor genes, on the other hand, normally act to regulate cell growth and prevent uncontrolled cell division. When these genes are inactivated or mutated, their protective functions are lost, leading to the development of cancer. This is typically due to loss of function mutations. Examples include the TP53 and RB1 genes.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B</span></strong><span style=\"font-size:12.0pt\">. Proto-oncogenes are not typically inactivated in cancer; they are activated or overexpressed. Tumor suppressor genes are often inactivated or under expressed in cancer.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.</span></strong><span style=\"font-size:12.0pt\"> Both proto-oncogenes and tumor suppressor genes can be involved in both malignant and benign tumors.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D.</span></strong><span style=\"font-size:12.0pt\"> Proto-oncogenes and tumor suppressor genes can encode a variety of proteins, not limited to growth factors and growth factor receptors.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Proto-oncogenes and tumor suppressor genes are two key classes of genes involved in cancer development. Proto-oncogenes promote cell growth and proliferation and can lead to cancer when mutated to gain function. Tumor suppressor genes normally inhibit cell growth, and their inactivation or loss of function can contribute to cancer development.</span></span></p>",
      "correct_choice_id": 78957,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19752,
      "choices": [
        {
          "id": 78969,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Point mutation in the p53 gene </span></span></p>"
        },
        {
          "id": 78970,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Deletion of the RB1 gene </span></span></p>"
        },
        {
          "id": 78971,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hypermethylation of the promoter region of a tumor suppressor gene </span></span></p>"
        },
        {
          "id": 78972,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Translocation between chromosomes 9 and 22</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Which of the following is an example of an epigenetic change that can contribute to cancer development?</span></span></span></p>",
      "unique_key": "Q3588472",
      "question_audio": null,
      "question_video": null,
      "map_id": 16556490,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C) Hypermethylation of the promoter region of a tumor suppressor gene</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Epigenetic changes, such as DNA methylation, can alter gene expression without changing the DNA sequence itself. Hypermethylation of tumor suppressor gene promoters can silence their expression, leading to cancer development. The other options represent genetic mutations, not epigenetic changes.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><span style=\"font-size:12.0pt\">:</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Point mutation in the p53 gene:</span></strong><span style=\"font-size:12.0pt\"> This is a genetic alteration where a single nucleotide in the DNA sequence of the p53 gene is changed. This can lead to the production of a dysfunctional p53 protein, which is a tumor suppressor. &nbsp; </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Deletion of the RB1 gene:</span></strong><span style=\"font-size:12.0pt\"> This is also a genetic alteration where a portion of the RB1 gene, another tumor suppressor, is removed. The absence of the RB1 protein can contribute to uncontrolled cell growth. &nbsp; </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Translocation between chromosomes 9 and 22:</span></strong><span style=\"font-size:12.0pt\"> This is a chromosomal rearrangement where a piece of chromosome 9 is transferred to chromosome 22, and vice versa. This translocation creates a new fusion gene, often the BCR-ABL gene, which drives the development of chronic myeloid leukemia (CML).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Epigenetic modifications, like DNA methylation, play a significant role in carcinogenesis.</span></span></p>",
      "correct_choice_id": 78971,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19753,
      "choices": [
        {
          "id": 78973,
          "text": "<p><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">E2 </span></span></p>"
        },
        {
          "id": 78974,
          "text": "<p><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">E4 </span></span></p>"
        },
        {
          "id": 78975,
          "text": "<p><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">E6</span></span></p>"
        },
        {
          "id": 78976,
          "text": "<p><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">E8</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following HPV genes is MOST directly implicated in the development of cervical cancer?</span></span></p>",
      "unique_key": "Q4310856",
      "question_audio": null,
      "question_video": null,
      "map_id": 16556491,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><strong>C) E6</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">E6 and E7 are the primary oncogenes of HPV. E6 inactivates p53, a tumor suppressor protein, while E7 inhibits the retinoblastoma (Rb) protein, both of which are critical for cell cycle regulation. &nbsp;</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. E2:</span></strong><span style=\"font-size:12.0pt\"> E2 is involved in viral replication and gene expression regulation. While important for the HPV lifecycle, it&#39;s not directly implicated in cellular transformation and cancer development.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. E4:</span></strong><span style=\"font-size:12.0pt\"> E4 plays a role in viral release and assembly. It&#39;s not considered a major oncogenic protein in the context of cervical cancer.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. E8:</span></strong><span style=\"font-size:12.0pt\"> There is no E8 gene in the HPV genome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The E6 and E7 proteins are the primary oncoproteins of HPV that drive the development of cervical cancer by interfering with critical cellular pathways that regulate cell growth and survival.</span></span></p>",
      "correct_choice_id": 78975,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19757,
      "choices": [
        {
          "id": 78989,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">CDKN2A (p16INK4A) mutation </span></span></p>"
        },
        {
          "id": 78990,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">CDKN1B (p27) mutation</span></span></p>"
        },
        {
          "id": 78991,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">CCND1 amplification</span></span></p>"
        },
        {
          "id": 78992,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">TP53 mutation</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A patient presents with mantle cell lymphoma (MCL). Which of the following genetic alterations is MOST likely associated with this malignancy?</span></span></p>",
      "unique_key": "Q4299528",
      "question_audio": null,
      "question_video": null,
      "map_id": 16556492,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C) CCND1 amplification</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The image shows that CCND1 amplification is associated with MCL. CCND1 encodes Cyclin D1, a protein that promotes the G1/S phase transition in the cell cycle. Amplification of this gene leads to overexpression of Cyclin D1 and uncontrolled cell proliferation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. CDKN2A (p16INK4A) mutation:</span></strong><span style=\"font-size:12.0pt\"> While CDKN2A mutations can be seen in various cancers, they are more commonly associated with melanoma and other solid tumors. In mantle cell lymphoma, CDKN2A deletions are associated with poor prognosis but are not the primary driver of the disease.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. CDKN1B (p27) mutation:</span></strong><span style=\"font-size:12.0pt\"> Mutations in CDKN1B are associated with MEN4 syndrome (multiple endocrine neoplasia type 4) and can be seen in other cancers, but not typically in mantle cell lymphoma.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. TP53 mutation:</span></strong><span style=\"font-size:12.0pt\"> TP53 is a tumor suppressor gene, and mutations are found in various cancers. While TP53 mutations can occur in MCL and are associated with a worse prognosis, they are not the primary genetic alteration driving the disease.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">CCND1 amplification is a hallmark of mantle cell lymphoma.</span></span></p>",
      "correct_choice_id": 78991,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19758,
      "choices": [
        {
          "id": 78993,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Inhibition of cyclin-dependent kinases (CDKs) in the G1/S phase transition</span></span></p>"
        },
        {
          "id": 78994,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Activation of topoisomerase II in the S phase</span></span></p>"
        },
        {
          "id": 78995,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Inhibition of microtubule formation in the M phase</span></span></p>"
        },
        {
          "id": 78996,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Activation of DNA repair enzymes in the G2 phase</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 45-year-old woman is diagnosed with breast cancer and is referred to an oncologist for treatment. The tumor is found to be estrogen receptor-positive and HER2-negative. The oncologist discusses the use of a targeted therapy that specifically interferes with the cell cycle of cancer cells, thereby inhibiting their proliferation. The medication targets a specific phase of the cell cycle, leading to cell cycle arrest and eventual apoptosis of the cancer cells. Which of the following best describes the mechanism of action of the medication likely prescribed to this patient?</span></span></p>",
      "unique_key": "Q7255748",
      "question_audio": null,
      "question_video": null,
      "map_id": 16556493,
      "difficulty_level": "difficult",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans</span></strong><span style=\"font-size:12.0pt\">. <strong>A) Inhibition of cyclin-dependent kinases (CDKs) in the G1/S phase transition</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A</span></strong><span style=\"font-size:12.0pt\">:</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In estrogen receptor-positive, HER2-negative breast cancer, a common targeted therapy is the use of CDK4/6 inhibitors, such as palbociclib, ribociclib, or abemaciclib. These medications work by inhibiting cyclin-dependent kinases 4 and 6 (CDK4/6), which are crucial for the progression of the cell cycle from the G1 phase to the S phase. By inhibiting these kinases, the medication induces cell cycle arrest at the G1/S transition, preventing cancer cells from replicating their DNA and dividing. This leads to a reduction in tumor growth and can enhance the effectiveness of other therapies.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Activation of topoisomerase II in the S phase</span></strong><span style=\"font-size:12.0pt\">: Topoisomerase II inhibitors, such as etoposide, work by interfering with the action of topoisomerase II, an enzyme involved in DNA replication and cell division during the S phase. This mechanism is not specific to CDK inhibitors used in breast cancer treatment.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Inhibition of microtubule formation in the M phase</span></strong><span style=\"font-size:12.0pt\">: Microtubule inhibitors, such as taxanes (e.g., paclitaxel), target the M phase of the cell cycle by preventing the formation of microtubules, which are essential for chromosome separation during cell division. This mechanism is different from that of CDK inhibitors.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Activation of DNA repair enzymes in the G2 phase</span></strong><span style=\"font-size:12.0pt\">: This option is not a common mechanism for targeted therapy in breast cancer. Drugs that target DNA repair pathways typically work by inhibiting, not activating, DNA repair enzymes to prevent cancer cells from repairing DNA damage.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cyclin-dependent kinase (CDK) inhibitors, such as palbociclib, ribociclib, and abemaciclib, are used in the treatment of estrogen receptor-positive, HER2-negative breast cancer. They work by inhibiting CDK4/6, leading to cell cycle arrest at the G1/S transition and preventing cancer cell proliferation.</span></span></p>",
      "correct_choice_id": 78993,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19760,
      "choices": [
        {
          "id": 79001,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">BRCA1 mutation </span></span></p>"
        },
        {
          "id": 79002,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">MUTYH mutation </span></span></p>"
        },
        {
          "id": 79003,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">MSH2 mutation </span></span></p>"
        },
        {
          "id": 79004,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">ATM mutation</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 28-year-old woman presents with a family history of early-onset colon cancer and multiple family members affected by various types of cancer. Which of the following genetic mutations is MOST likely responsible for her increased cancer risk?</span></span></p>",
      "unique_key": "Q5691803",
      "question_audio": null,
      "question_video": null,
      "map_id": 16556494,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C) MSH2 mutation</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient&#39;s presentation suggests Lynch syndrome (Hereditary Non-Polyposis Colorectal Cancer or HNPCC), which is caused by germline mutations in mismatch repair (MMR) genes, including MSH2. BRCA1 is associated with breast and ovarian cancer, MUTYH with a specific type of colorectal cancer, and ATM with ataxia-telangiectasia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. BRCA1 mutation:</span></strong><span style=\"font-size:12.0pt\"> BRCA1 mutations are primarily associated with increased risks of breast and ovarian cancers. While they can increase the risk of other cancers, the patient&#39;s family history of colon cancer makes this less likely.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. MUTYH mutation:</span></strong><span style=\"font-size:12.0pt\"> MUTYH mutations are associated with MUTYH-associated polyposis (MAP), a hereditary condition that increases the risk of colorectal cancer. However, MAP usually presents with multiple polyps, and the patient&#39;s family history doesn&#39;t necessarily fit this pattern.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. ATM mutation:</span></strong><span style=\"font-size:12.0pt\"> ATM mutations are associated with ataxia-telangiectasia, a rare neurodegenerative disorder characterized by ataxia, telangiectasias (small dilated blood vessels), and immune deficiencies. While individuals with ataxia-telangiectasia have an increased risk of certain cancers, the presentation in this question doesn&#39;t match the typical features of this condition.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">MSH2 mutations are associated with Lynch syndrome, a hereditary cancer syndrome that significantly increases the risk of various cancers, including colorectal, endometrial, and ovarian cancer.</span></span></span></p>",
      "correct_choice_id": 79003,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19761,
      "choices": [
        {
          "id": 79005,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Non-homologous end joining (NHEJ)</span></span></p>"
        },
        {
          "id": 79006,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Base excision repair (BER)</span></span></p>"
        },
        {
          "id": 79007,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Homologous recombination (HR)</span></span></p>"
        },
        {
          "id": 79008,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Single-strand break repair</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 38-year-old woman presents to your clinic with a newly discovered breast mass. Her family history is significant for multiple cases of breast and ovarian cancer, including her mother and sister. Genetic testing reveals a germline BRCA1 mutation. Which of the following DNA repair pathways is MOST likely deficient in this patient, contributing to her increased cancer risk?</span></span></p>",
      "unique_key": "Q7115506",
      "question_audio": null,
      "question_video": null,
      "map_id": 16556495,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C) Homologous recombination (HR)</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">BRCA1 is a tumor suppressor gene that plays a crucial role in homologous recombination (HR), a DNA repair mechanism responsible for repairing double-stranded DNA breaks. A germline mutation in BRCA1 disrupts the HR pathway, leading to genomic instability and increasing the risk of developing breast and ovarian cancers.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Non-homologous end joining (NHEJ):</span></strong><span style=\"font-size:12.0pt\"> While important for DNA repair, NHEJ is not the primary pathway affected by BRCA1 mutations.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Base excision repair (BER):</span></strong><span style=\"font-size:12.0pt\"> BER is primarily responsible for repairing single-base DNA damage and is not directly affected by BRCA1 mutations.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Single-strand break repair:</span></strong><span style=\"font-size:12.0pt\"> This is a broader term encompassing several pathways, including BER and PARP. While PARP inhibitors are used in BRCA-mutant cancers, the primary defect lies in HR.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">BRCA1 mutations lead to a deficiency in homologous recombination (HR), a critical DNA repair mechanism. This defect contributes to genomic instability and significantly increases the risk of breast and ovarian cancers in affected individuals.</span></span></span></p>",
      "correct_choice_id": 79007,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19762,
      "choices": [
        {
          "id": 79009,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Base excision repair (BER) </span></span></p>"
        },
        {
          "id": 79010,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Nucleotide excision repair (NER)</span></span></p>"
        },
        {
          "id": 79011,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Homologous recombination (HR)</span></span></p>"
        },
        {
          "id": 79012,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Non-homologous end joining (NHEJ)</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 5-year-old child is brought to your clinic by their parents, who are concerned about their child&#39;s extreme sensitivity to sunlight. The child easily sunburns and has developed multiple freckles and skin lesions after minimal sun exposure. On examination, you notice dry skin and patches of hypopigmentation. You suspect an underlying genetic disorder affecting DNA repair mechanisms. Which of the following DNA repair pathways is MOST likely deficient in this child?</span></span></p>",
      "unique_key": "Q6481675",
      "question_audio": null,
      "question_video": null,
      "map_id": 16556496,
      "difficulty_level": "difficult",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>B) Nucleotide excision repair (NER)</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The child&#39;s clinical presentation of photosensitivity, skin lesions, and pigmentary changes is highly suggestive of xeroderma pigmentosum (XP). XP is a rare autosomal recessive disorder characterized by defective nucleotide excision repair (NER). NER is the primary mechanism for repairing DNA damage caused by ultraviolet (UV) radiation from the sun.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Base excision repair (BER):</span></strong><span style=\"font-size:12.0pt\"> BER primarily repairs damage to single bases in DNA, often caused by oxidation or alkylation. While important, it&#39;s not the primary pathway for repairing the type of damage caused by UV radiation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Homologous recombination (HR):</span></strong><span style=\"font-size:12.0pt\"> HR is a complex process used to repair double-stranded DNA breaks. While critical for genome stability, it&#39;s not the main mechanism for repairing UV-induced DNA damage.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Non-homologous end joining (NHEJ):</span></strong><span style=\"font-size:12.0pt\"> Similar to HR, NHEJ repairs double-stranded breaks but does not play a major role in repairing UV-induced damage.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The inability to repair UV-induced DNA damage in XP leads to a significantly increased risk of skin cancer at a young age, as well as other complications like ocular problems and neurological abnormalities. Early diagnosis and strict sun protection measures are crucial for managing XP.</span></span></span></p>",
      "correct_choice_id": 79010,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53460,
      "choices": [
        {
          "id": 213321,
          "text": "<p><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Apoptosis </span></span></p>"
        },
        {
          "id": 213322,
          "text": "<p><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Necroptosis </span></span></p>"
        },
        {
          "id": 213323,
          "text": "<p><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pyroptosis </span></span></p>"
        },
        {
          "id": 213324,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Necrosis</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A researcher is investigating a new drug that inhibits the formation of the inflammasome complex. Which of the following types of cell death would be MOST directly affected by this drug?</span></span></p>",
      "unique_key": "Q1372805",
      "question_audio": null,
      "question_video": null,
      "map_id": 16556497,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C) Pyroptosis</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The inflammasome is a key component of the pyroptosis pathway, responsible for activating caspase-1 and ultimately leading to inflammatory cell death. Inhibiting the inflammasome would therefore block pyroptosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Apoptosis:</span></strong><span style=\"font-size:12.0pt\"> Apoptosis is a programmed cell death pathway, but it is not directly dependent on the inflammasome. It involves a different set of caspases (caspase-3, -6, -7) and is not typically associated with the same inflammatory response as pyroptosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Necroptosis:</span></strong><span style=\"font-size:12.0pt\"> Necroptosis is another form of programmed cell death, but it is regulated by the RIPK1-RIPK3-MLKL pathway, not the inflammasome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Necrosis:</span></strong><span style=\"font-size:12.0pt\"> Necrosis is an unregulated form of cell death that is typically caused by injury or trauma. It is not a programmed process and is not mediated by the inflammasome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The inflammasome is a multiprotein complex that plays a central role in pyroptosis. It senses danger signals and activates caspase-1, leading to the production of pro-inflammatory cytokines and ultimately cell death with membrane rupture. By inhibiting the inflammasome, the drug would directly block the pyroptotic pathway.</span></span></span></p>",
      "correct_choice_id": 213323,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19763,
      "choices": [
        {
          "id": 79013,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Mutation in BRCA1 </span></span></span></p>"
        },
        {
          "id": 79014,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Amplification of HER2 </span></span></span></p>"
        },
        {
          "id": 79015,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Loss of function mutation in VHL </span></span></span></p>"
        },
        {
          "id": 79016,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Activation of KRAS</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 35-year-old patient presents with painless hematuria and flank pain. Imaging reveals a renal mass with characteristic features of clear cell renal cell carcinoma (RCC). Which of the following genetic alterations is MOST likely involved in the pathogenesis of this tumor?</span></span></p>",
      "unique_key": "Q1660386",
      "question_audio": null,
      "question_video": null,
      "map_id": 16556498,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">C) Loss of function mutation in VHL</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Clear cell RCC is strongly associated with inactivation of the von Hippel-Lindau (VHL) tumor suppressor gene. This leads to stabilization of hypoxia-inducible factor (HIF), promoting angiogenesis and tumor growth.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Mutation in BRCA1:</span></strong><span style=\"font-size:12.0pt\"> BRCA1 is a tumor suppressor gene primarily associated with breast and ovarian cancers. While it can be involved in other cancers, it&#39;s not the primary driver of clear cell renal cell carcinoma (RCC).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Amplification of HER2:</span></strong><span style=\"font-size:12.0pt\"> HER2 amplification is a key feature of certain breast cancers and some other malignancies, but not clear cell RCC.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Activation of KRAS:</span></strong><span style=\"font-size:12.0pt\"> KRAS is an oncogene involved in various cancers, including some types of lung and colon cancer. It is not the hallmark of clear cell RCC.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The VHL gene plays a crucial role in oxygen sensing and regulation of blood vessel growth. When VHL is inactivated, it leads to the stabilization and activation of hypoxia-inducible factor (HIF), which promotes angiogenesis (new blood vessel formation) and tumor growth. This is why VHL loss-of-function mutations are so strongly linked to clear cell RCC.</span></span></p>",
      "correct_choice_id": 79015,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19765,
      "choices": [
        {
          "id": 79021,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">PD-1</span></span></p>"
        },
        {
          "id": 79022,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">PD-L1</span></span></p>"
        },
        {
          "id": 79023,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">CTLA-4</span></span></p>"
        },
        {
          "id": 79024,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">CD80/86</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 52-year-old man with metastatic melanoma has progressed on previous therapy. You are considering starting him on an immune checkpoint inhibitor along with nivolumab after which you are planning to keep him on nibolumab. Which of the following immune checkpoint molecules is the DIRECT target for the drug which you have planned to give for this patient along with nivolumab?</span></span></p>",
      "unique_key": "Q6417400",
      "question_audio": null,
      "question_video": null,
      "map_id": 16556499,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C) CTLA-4</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ipilimumab is a monoclonal antibody that specifically targets CTLA-4 (Cytotoxic T-Lymphocyte-Associated protein 4). CTLA-4 is an inhibitory receptor on T cells that, when bound to its ligands (CD80/CD86) on antigen-presenting cells, downregulates T-cell activation. By blocking CTLA-4, ipilimumab releases this inhibition, allowing T cells to more effectively recognize and attack cancer cells. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. PD-1:</span></strong><span style=\"font-size:12.0pt\"> PD-1 is another inhibitory checkpoint on T cells, but it&#39;s targeted by different drugs like nivolumab and pembrolizumab.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. PD-L1:</span></strong><span style=\"font-size:12.0pt\"> PD-L1 is the ligand for PD-1, and it&#39;s also targeted by different drugs like atezolizumab and durvalumab.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. CD80/86:</span></strong><span style=\"font-size:12.0pt\"> These are the ligands for CTLA-4, but ipilimumab doesn&#39;t directly bind to them; it binds to CTLA-4 itself.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Understanding the specific targets of immune checkpoint inhibitors is crucial for selecting the right therapy for different types of cancer and managing potential immune-related side effects.</span></span></p>",
      "correct_choice_id": 79023,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19767,
      "choices": [
        {
          "id": 79029,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Oxidative phosphorylation</span></span></p>"
        },
        {
          "id": 79030,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The Cori cycle </span></span></p>"
        },
        {
          "id": 79031,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The Warburg effect</span></span></p>"
        },
        {
          "id": 79032,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Gluconeogenesis</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A researcher is studying the metabolic profile of cancer cells and notices that they primarily produce energy through glycolysis, even in the presence of oxygen. This phenomenon is BEST described as:</span></span></span></p>",
      "unique_key": "Q7911880",
      "question_audio": null,
      "question_video": null,
      "map_id": 16556500,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">C) The Warburg effect</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The Warburg effect is the observation that cancer cells preferentially utilize aerobic glycolysis for energy production. This is in contrast to normal cells, which typically rely on oxidative phosphorylation in the presence of oxygen.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Oxidative phosphorylation:</span></strong><span style=\"font-size:12.0pt\"> This is the normal process of energy production in cells with sufficient oxygen. It occurs in the mitochondria and is much more efficient at generating ATP than glycolysis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. The Cori cycle:</span></strong><span style=\"font-size:12.0pt\"> This is a metabolic pathway that involves the interconversion of lactate and glucose between the liver and muscles. While lactate is a byproduct of glycolysis, the Cori cycle itself isn&#39;t the primary energy production method in cancer cells.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Gluconeogenesis:</span></strong><span style=\"font-size:12.0pt\"> This is the process of synthesizing glucose from non-carbohydrate sources (like amino acids or lactate). While cancer cells may engage in gluconeogenesis, it&#39;s not the main energy-producing pathway they rely on.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The Warburg effect is a hallmark of cancer metabolism and has implications for both cancer diagnosis and potential therapeutic targets.</span></span></span></p>",
      "correct_choice_id": 79031,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53463,
      "choices": [
        {
          "id": 213333,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Neurofibromatosis type 2</span></span></p>"
        },
        {
          "id": 213334,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tuberous sclerosis complex</span></span></p>"
        },
        {
          "id": 213335,
          "text": "<p><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Von Hippel-Lindau disease</span></span></p>"
        },
        {
          "id": 213336,
          "text": "<p><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Li-Fraumeni syndrome</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 32-year-old male presents with progressive headaches, gait instability, and visual disturbances. MRI was taken and shown below. Patient also has, multiple retinal angiomas. His family history is notable for his father died of uncontrolled hypertension during his 50s and his paternal side uncle was diagnosed with a brain tumor and uncontrolled hypertension along with frequent anger outbursts seeking psychiatric counselling. Which of the following is the MOST likely diagnosis?</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/08/screenshot-2024-08-08-172814.jpg\" style=\"height:387px; width:400px\" /></span></span></p>",
      "unique_key": "Q1065130",
      "question_audio": null,
      "question_video": null,
      "map_id": 16556501,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C) Von Hippel-Lindau disease</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The combination of a cerebellar hemangioblastoma, retinal angiomas, and a strong family history of similar tumors (brain tumor in the paternal uncle) and possible pheochromocytoma (uncontrolled hypertension, anger outbursts suggesting catecholamine excess) strongly suggests Von Hippel-Lindau (VHL) disease. VHL disease is an autosomal dominant inherited disorder that predisposes individuals to a variety of tumors, including, Hemangioblastomas, Renal cell carcinoma, Pheochromocytoma. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Neurofibromatosis type 2:</span></strong><span style=\"font-size:12.0pt\"> This condition is associated with bilateral vestibular schwannomas (tumors of the nerve responsible for hearing and balance) and other nerve tumors, not the specific findings in this case.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Tuberous sclerosis complex:</span></strong><span style=\"font-size:12.0pt\"> This syndrome is associated with benign tumors in various organs, including the brain, kidneys, heart, eyes, lungs, and skin. The characteristic brain tumors are cortical tubers and subependymal giant cell astrocytomas, not hemangioblastomas.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Li-Fraumeni syndrome:</span></strong><span style=\"font-size:12.0pt\"> This syndrome predisposes individuals to a wide range of cancers, including sarcomas, breast cancer, brain tumors, and leukemia. It is not typically associated with the specific combination of findings in this patient.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The presence of a cerebellar hemangioblastoma and retinal angiomas, especially in conjunction with a suggestive family history, should raise strong suspicion for Von Hippel-Lindau disease. Early diagnosis and surveillance are crucial for managing this condition and preventing complications.</span></span></span></p>",
      "correct_choice_id": 213335,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "ImageBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53465,
      "choices": [
        {
          "id": 213341,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">PRKAR1A </span></span></p>"
        },
        {
          "id": 213342,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">CDKN2A </span></span></p>"
        },
        {
          "id": 213343,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">SDH </span></span></p>"
        },
        {
          "id": 213344,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">MET</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 28-year-old man presents with multiple pigmented skin lesions and cardiac myxomas. He also reports a family history of sudden cardiac death. Which gene is MOST likely to be mutated in this patient?</span></span></p>",
      "unique_key": "Q9113611",
      "question_audio": null,
      "question_video": null,
      "map_id": 16556502,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>A) PRKAR1A</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The combination of pigmented skin lesions, cardiac myxomas, and a family history of sudden cardiac death suggests Carney complex, which is caused by mutations in the PRKAR1A gene.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. CDKN2A</span></strong><span style=\"font-size:12.0pt\">: This gene is associated with melanoma and pancreatic cancer in the context of familial atypical multiple mole melanoma (FAMMM) syndrome. While pigmented skin lesions can be present in FAMMM, cardiac myxomas and a family history of sudden cardiac death are not characteristic features.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. SDH</span></strong><span style=\"font-size:12.0pt\">: Mutations in SDH genes are linked to hereditary paraganglioma-pheochromocytoma syndrome, which primarily manifests with tumors of the adrenal glands and nervous system. Cardiac myxomas and pigmented skin lesions are not associated with this syndrome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. MET</span></strong><span style=\"font-size:12.0pt\">: MET mutations are involved in hereditary papillary renal cell carcinoma. This condition is not typically associated with cardiac myxomas or pigmented skin lesions.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u>&nbsp; </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The specific constellation of findings in this patient, including pigmented skin lesions, cardiac myxomas, and a family history of sudden cardiac death, is strongly suggestive of Carney complex, a rare autosomal dominant disorder caused by mutations in the PRKAR1A gene.</span></span></p>",
      "correct_choice_id": 213341,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53467,
      "choices": [
        {
          "id": 213349,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Homologous recombination (HR)</span></span></p>"
        },
        {
          "id": 213350,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">DNA crosslink repair</span></span></p>"
        },
        {
          "id": 213351,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Non-homologous end joining (NHEJ)</span></span></p>"
        },
        {
          "id": 213352,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Mismatch repair (MMR)</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 7-year-old boy is brought to the pediatrician due to concerns about his small stature and sun sensitivity. He has also had recurrent respiratory infections. On physical examination, he is noted to have a photosensitive rash on his face, microcephaly, and low body weight for his age. Which of the following DNA repair pathways is MOST likely deficient in this child?</span></span></span></p>",
      "unique_key": "Q3163636",
      "question_audio": null,
      "question_video": null,
      "map_id": 16556503,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Homologous recombination (HR)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The child&#39;s clinical presentation, including short stature, photosensitive rash, microcephaly, immunodeficiency, and predisposition to leukemia and lymphoma, is highly suggestive of Bloom syndrome. Bloom syndrome is caused by mutations in the BLM gene, which encodes a protein essential for homologous recombination (HR). HR is a critical DNA repair mechanism that repairs double-strand DNA breaks. Defects in HR lead to genomic instability and increased susceptibility to cancer.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. DNA crosslink repair:</span></strong><span style=\"font-size:12.0pt\"> Defects in DNA crosslink repair are seen in Fanconi anemia, which presents with bone marrow failure, developmental abnormalities, and increased risk of leukemia, but not the other features seen in this patient.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Non-homologous end joining (NHEJ):</span></strong><span style=\"font-size:12.0pt\"> NHEJ is another DNA repair pathway that repairs double-strand breaks. While important for maintaining genomic stability, it&#39;s not the primary pathway affected in Bloom syndrome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Mismatch repair (MMR):</span></strong><span style=\"font-size:12.0pt\"> MMR corrects errors that occur during DNA replication. Defects in MMR are seen in Lynch syndrome, which is associated with an increased risk of colorectal and other cancers, but not the characteristic features of Bloom syndrome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Bloom syndrome is a rare genetic disorder characterized by growth retardation, sun sensitivity, immunodeficiency, and predisposition to various cancers. It is caused by mutations in the BLM gene, which leads to defective homologous recombination and genomic instability.</span></span></span></p>",
      "correct_choice_id": 213349,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19770,
      "choices": [
        {
          "id": 79041,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Vincristine </span></span></p>"
        },
        {
          "id": 79042,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Paclitaxel </span></span></p>"
        },
        {
          "id": 79043,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Eribulin </span></span></p>"
        },
        {
          "id": 79044,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">5-Fluorouracil</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A patient with breast cancer is being treated with a drug that stabilizes microtubules, preventing their depolymerization. Which of the following drugs is MOST likely being used?</span></span></p>",
      "unique_key": "Q4179585",
      "question_audio": null,
      "question_video": null,
      "map_id": 16556504,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">B) Paclitaxel</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The image clearly states that taxanes like paclitaxel stabilize microtubules. Vinca alkaloids and eribulin inhibit microtubule formation, while 5-FU is an antimetabolite, not an anti-microtubule agent.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Vincristine:</span></strong><span style=\"font-size:12.0pt\"> Vincristine is a vinca alkaloid that destabilizes microtubules by binding to tubulin and preventing its polymerization. This leads to disruption of the mitotic spindle and cell death.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Eribulin:</span></strong><span style=\"font-size:12.0pt\"> Eribulin is also a microtubule-destabilizing agent, though its mechanism of action is slightly different from vinca alkaloids. It binds to the plus end of microtubules, preventing their growth and leading to mitotic arrest.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. 5-Fluorouracil (5-FU):</span></strong><span style=\"font-size:12.0pt\"> 5-FU is an antimetabolite that interferes with DNA synthesis. It has no direct effect on microtubules.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The key difference lies in the mechanism of action. Paclitaxel stabilizes microtubules, preventing their normal breakdown, which is essential for cell division. In contrast, vinca alkaloids and eribulin destabilize microtubules, also disrupting cell division but through a different process.</span></span></span></p>",
      "correct_choice_id": 79042,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19772,
      "choices": [
        {
          "id": 79049,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">G1 phase </span></span></p>"
        },
        {
          "id": 79050,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">S phase</span></span></p>"
        },
        {
          "id": 79051,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">G2 phase</span></span></p>"
        },
        {
          "id": 79052,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">M phase</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 65-year-old man with a 40 pack-year smoking history presents with a persistent cough and hemoptysis. Imaging reveals a central lung mass, and biopsy confirms small cell lung cancer (SCLC). He is started on a chemotherapy regimen including etoposide. Etoposide exerts its anti-cancer effects by targeting a specific phase of the cell cycle. During which phase is etoposide MOST effective?</span></span></p>",
      "unique_key": "Q5605819",
      "question_audio": null,
      "question_video": null,
      "map_id": 16556505,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">D) M phase</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Etoposide is a topoisomerase II inhibitor. Topoisomerase II is an enzyme that helps unwind DNA during replication. Etoposide traps the topoisomerase II enzyme on the DNA, leading to the accumulation of double-stranded DNA breaks. These breaks are most detrimental during mitosis (M phase) when the cell is actively dividing and trying to separate its chromosomes.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. G1 phase:</span></strong><span style=\"font-size:12.0pt\"> This is the phase where the cell grows and prepares for DNA replication. Etoposide&#39;s mechanism doesn&#39;t directly target processes in this phase.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. S phase:</span></strong><span style=\"font-size:12.0pt\"> This is the phase of DNA replication. While DNA damage can occur here, etoposide&#39;s primary action is on the M phase.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. G2 phase:</span></strong><span style=\"font-size:12.0pt\"> This phase involves further cell growth and preparation for mitosis. Again, etoposide&#39;s primary target is the M phase.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Etoposide is a topoisomerase II inhibitor that is most effective during the M phase of the cell cycle, where it disrupts chromosome segregation and leads to cell death. Understanding the cell cycle specificity of chemotherapy drugs is crucial for optimizing treatment regimens.</span></span></p>",
      "correct_choice_id": 79052,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19773,
      "choices": [
        {
          "id": 79053,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Directly blocking DNA synthesis </span></span></p>"
        },
        {
          "id": 79054,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Preventing cell division by disrupting microtubules</span></span></p>"
        },
        {
          "id": 79055,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Trapping an enzyme involved in DNA unwinding, leading to DNA breaks</span></span></p>"
        },
        {
          "id": 79056,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Inserting itself into DNA, causing structural damage</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 55-year-old woman with platinum-resistant ovarian cancer is started on topotecan. You counsel her that this medication works by:</span></span></span></p>",
      "unique_key": "Q9131830",
      "question_audio": null,
      "question_video": null,
      "map_id": 16556506,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">C) Trapping an enzyme involved in DNA unwinding, leading to DNA breaks </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Topotecan is a topoisomerase I inhibitor.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Topoisomerase I is essential for relieving torsional stress during DNA replication by creating transient single-stranded breaks.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Topotecan prevents the topoisomerase I enzyme from resealing these breaks, leading to DNA damage and ultimately cell death. &nbsp; </span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Directly blocking DNA synthesis:</span></strong><span style=\"font-size:12.0pt\"> While topotecan ultimately disrupts DNA replication, it doesn&#39;t directly block DNA synthesis in the same way that antimetabolites do. Antimetabolites, like 5-FU, are structurally similar to DNA building blocks and get incorporated into the DNA strand, thus halting its growth.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Preventing cell division by disrupting microtubules:</span></strong><span style=\"font-size:12.0pt\"> This is the mechanism of action of drugs like taxanes (paclitaxel, docetaxel) and vinca alkaloids (vincristine, vinblastine). They interfere with the formation of the mitotic spindle, which is essential for cell division.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Inserting itself into DNA, causing structural damage:</span></strong><span style=\"font-size:12.0pt\"> This describes the mechanism of action of anthracyclines (doxorubicin, daunorubicin). These drugs intercalate between DNA base pairs, leading to distortion of the DNA structure and interfering with replication and transcription.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Topotecan targets topoisomerase I, disrupting DNA replication and causing lethal DNA damage in cancer cells. &nbsp; </span></span></p>",
      "correct_choice_id": 79055,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19776,
      "choices": [
        {
          "id": 79065,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Nausea and vomiting</span></span></p>"
        },
        {
          "id": 79066,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Alopecia (hair loss)</span></span></p>"
        },
        {
          "id": 79067,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cardiotoxicity</span></span></p>"
        },
        {
          "id": 79068,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Myelosuppression (bone marrow suppression)</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 50-year-old woman with breast cancer has completed her primary treatment, which included several cycles of doxorubicin-containing chemotherapy. She is now in remission and attending a follow-up visit with her oncologist. Which of the following long-term complications is the oncologist MOST concerned about?</span></span></p>",
      "unique_key": "Q2007383",
      "question_audio": null,
      "question_video": null,
      "map_id": 16556507,
      "difficulty_level": "difficult",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Cardiotoxicity</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Doxorubicin, an anthracycline antibiotic used in chemotherapy, is known for its cumulative dose-dependent cardiotoxicity. This can manifest as heart failure, often years after treatment completion. Therefore, long-term cardiac monitoring is essential for patients who have received doxorubicin.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Nausea and vomiting:</span></strong><span style=\"font-size:12.0pt\"> While common during active chemotherapy treatment, nausea and vomiting are usually acute side effects and not a significant long-term concern.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Alopecia (hair loss):</span></strong><span style=\"font-size:12.0pt\"> Hair loss is another common acute side effect of chemotherapy, but hair usually regrows after treatment is completed.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Myelosuppression:</span></strong><span style=\"font-size:12.0pt\"> Myelosuppression (suppression of bone marrow function, leading to decreased blood cell counts) is a significant side effect during active chemotherapy. However, it typically resolves once treatment is stopped and is not a major long-term concern in the same way as cardiotoxicity.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Anthracyclines, like doxorubicin, can cause delayed cardiotoxicity. Patients who have received these drugs need long-term cardiac follow-up, even years after completing treatment.</span></span></span></p>",
      "correct_choice_id": 79067,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19777,
      "choices": [
        {
          "id": 79069,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">G1 phase</span></span></p>"
        },
        {
          "id": 79070,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">S phase</span></span></p>"
        },
        {
          "id": 79071,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">G2 phase </span></span></p>"
        },
        {
          "id": 79072,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">M phase</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 45-year-old man with testicular cancer is scheduled to receive bleomycin- containing chemotherapy regimen. Bleomycin is MOST effective during which phase of the cell cycle?</span></span></p>",
      "unique_key": "Q5188109",
      "question_audio": null,
      "question_video": null,
      "map_id": 16556508,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) G2 phase</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Bleomycin&#39;s mechanism of action involves the generation of free radicals that cause DNA strand breaks. These breaks are most detrimental to the cell during the G2 phase, when the cell is checking for errors in its replicated DNA before proceeding to mitosis (cell division).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">&nbsp;<u>Explanation:</u></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. G1 phase:</span></strong><span style=\"font-size:12.0pt\"> This is the phase where the cell grows and prepares for DNA replication. Bleomycin&#39;s DNA-damaging effects are not specifically targeted to this phase.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. S phase:</span></strong><span style=\"font-size:12.0pt\"> This is the phase of DNA replication. While DNA damage can occur here, bleomycin&#39;s peak activity is in the G2 phase.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. M phase:</span></strong><span style=\"font-size:12.0pt\"> This is the phase of actual cell division (mitosis). While bleomycin-induced DNA damage can also affect mitosis, it&#39;s most potent during the G2 phase when the cell is actively preparing for division.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Bleomycin is a cell cycle-specific antitumor antibiotic that primarily targets the G2 phase of the cell cycle.</span></span></span></p>",
      "correct_choice_id": 79071,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53470,
      "choices": [
        {
          "id": 213361,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tamoxifen </span></span></p>"
        },
        {
          "id": 213362,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Anastrozole </span></span></p>"
        },
        {
          "id": 213363,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Fulvestrant </span></span></p>"
        },
        {
          "id": 213364,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Leuprolide</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A postmenopausal woman with breast cancer is found to have a tumor that overexpresses aromatase. Which of the following medications is MOST likely to be effective in treating this patient?</span></span></p>",
      "unique_key": "Q4542617",
      "question_audio": null,
      "question_video": null,
      "map_id": 16556509,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>B) Anastrozole </strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Aromatase inhibitors like anastrozole block the conversion of androgens to estrogens in peripheral tissues, particularly in postmenopausal women. This reduces estrogen levels, which can inhibit the growth of hormone-receptor-positive breast cancers. Tamoxifen is a selective estrogen receptor modulator (SERM) that blocks estrogen receptors but doesn&#39;t affect estrogen production. Fulvestrant is an estrogen receptor downregulator. Leuprolide is a gonadotropin-releasing hormone (GnRH) agonist used for ovarian suppression in premenopausal women.<strong> </strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Tamoxifen:</span></strong><span style=\"font-size:12.0pt\"> Tamoxifen is a Selective Estrogen Receptor Modulator (SERM) that acts as an estrogen antagonist in breast tissue but an agonist in other tissues like the bone and uterus. While it can be effective in some cases of hormone-receptor-positive breast cancer, it doesn&#39;t directly address the issue of increased estrogen production in tumors that overexpress aromatase.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Fulvestrant:</span></strong><span style=\"font-size:12.0pt\"> Fulvestrant is a Selective Estrogen Receptor Downregulator (SERD) that binds to and degrades estrogen receptors. While effective in hormone-receptor-positive breast cancer, it also doesn&#39;t directly target the increased estrogen production in this case.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Leuprolide:</span></strong><span style=\"font-size:12.0pt\"> Leuprolide is a Gonadotropin-Releasing Hormone (GnRH) agonist that suppresses ovarian function, leading to decreased estrogen production. However, it&#39;s primarily used in premenopausal women. In postmenopausal women, the ovaries are already inactive, and most estrogen production occurs in peripheral tissues through aromatase.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Aromatase inhibitors are effective in treating hormone-receptor-positive breast cancer in postmenopausal women by reducing estrogen production.</span></span></p>",
      "correct_choice_id": 213362,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53471,
      "choices": [
        {
          "id": 213365,
          "text": "<p><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">5-alpha reductase (5-AR)</span></span></p>"
        },
        {
          "id": 213366,
          "text": "<p><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Aromatase</span></span></p>"
        },
        {
          "id": 213367,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">17-alpha hydroxylase (17&alpha;1)</span></span></p>"
        },
        {
          "id": 213368,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">CYP17</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 65-year-old man with prostate cancer has been on androgen deprivation therapy (ADT) but recently shows signs of disease progression. His oncologist suspects that his tumor may be utilizing an alternative pathway to maintain androgen signalling. Which enzyme is MOST likely responsible for converting testosterone to a more potent androgen within the prostate, contributing to this resistance?</span></span></p>",
      "unique_key": "Q2533475",
      "question_audio": null,
      "question_video": null,
      "map_id": 16556510,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Ans. A) 5-alpha reductase (5-AR)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">5-alpha reductase converts testosterone to dihydrotestosterone (DHT), a more potent androgen that binds to the androgen receptor with higher affinity. Even in the setting of low testosterone levels due to ADT, some prostate cancers can upregulate 5-AR activity to continue growing.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">&nbsp;</span><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Aromatase:</span></strong><span style=\"font-size:12.0pt\"> Aromatase converts androgens to estrogens and is relevant in breast cancer, not prostate cancer.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. 17-alpha hydroxylase (17&alpha;1):</span></strong><span style=\"font-size:12.0pt\"> This enzyme is involved in the early steps of steroid hormone synthesis in the adrenal glands and gonads. It doesn&#39;t directly convert testosterone to DHT.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. CYP17:</span></strong><span style=\"font-size:12.0pt\"> CYP17 is another enzyme involved in steroid hormone synthesis, but it doesn&#39;t directly convert testosterone to DHT.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Understanding the role of 5-alpha reductase in androgen metabolism is important for comprehending mechanisms of resistance to hormone therapy in prostate cancer and for selecting appropriate treatment strategies.</span></span></p>",
      "correct_choice_id": 213365,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19779,
      "choices": [
        {
          "id": 79077,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Dexamethasone alone </span></span></span></p>"
        },
        {
          "id": 79078,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">5HT3 antagonist alone </span></span></span></p>"
        },
        {
          "id": 79079,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Dexamethasone + 5HT3 antagonist </span></span></span></p>"
        },
        {
          "id": 79080,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Dexamethasone + 5HT3 antagonist + NK1 receptor antagonist</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A patient is about to start a chemotherapy regimen containing high-dose cyclophosphamide (&gt;1500mg/m&sup2;). Which antiemetic regimen is MOST appropriate for preventing CINV in this patient?</span></span></span></p>",
      "unique_key": "Q7302794",
      "question_audio": null,
      "question_video": null,
      "map_id": 16556511,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Dexamethasone + 5HT3 antagonist + NK1 receptor antagonist</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">High-dose cyclophosphamide (&gt;1500mg/m<sup>2</sup>) as a high-risk emetogenic chemotherapy, requiring a combination of dexamethasone, a 5HT3 antagonist, and an NK1 receptor antagonist on days 1, 2, and 3 of the chemotherapy cycle.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Dexamethasone alone:</span></strong><span style=\"font-size:12.0pt\"> While dexamethasone has antiemetic properties, it is not sufficient on its own to prevent CINV in high-risk regimens like those involving high-dose cyclophosphamide.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. 5HT3 antagonist alone:</span></strong><span style=\"font-size:12.0pt\"> 5HT3 antagonists are effective antiemetics, but they are not potent enough to control CINV in high-risk settings when used alone.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Dexamethasone + 5HT3 antagonist:</span></strong><span style=\"font-size:12.0pt\"> This combination provides better control than either drug alone, but it may still be inadequate for high-risk chemotherapy. The addition of an NK1 receptor antagonist further enhances antiemetic efficacy in these cases.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational objective:</span></strong> </span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">High-risk emetogenic chemotherapy requires a triple-drug antiemetic regimen to effectively prevent CINV.</span></span></span></p>",
      "correct_choice_id": 79080,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19781,
      "choices": [
        {
          "id": 79085,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Her current chemotherapy regimen has a 15% risk of causing febrile neutropenia. </span></span></span></p>"
        },
        {
          "id": 79086,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">She has a history of febrile neutropenia from prior chemotherapy. </span></span></span></p>"
        },
        {
          "id": 79087,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">She develops a fever and her absolute neutrophil count (ANC) drops to 500/&micro;L during her current treatment. </span></span></span></p>"
        },
        {
          "id": 79088,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">She is also scheduled to receive radiation therapy to her chest wall after completing chemotherapy.</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">You are seeing a 60-year-old woman with newly diagnosed breast cancer scheduled to start chemotherapy with a regimen known to have a high risk of causing neutropenia. In which of the following scenarios is the use of G-CSF therapy MOST strongly indicated for this patient?</span></span></span></p>",
      "unique_key": "Q9220134",
      "question_audio": null,
      "question_video": null,
      "map_id": 16556512,
      "difficulty_level": "difficult",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) She has a history of febrile neutropenia from prior chemotherapy.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A history of febrile neutropenia is a strong indication for primary prophylaxis with G-CSF, even if the current chemotherapy regimen is not considered high-risk. G-CSF stimulates the production of neutrophils, reducing the risk of severe neutropenia and subsequent infections.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Her current chemotherapy regimen has a 15% risk of causing febrile neutropenia.</span></strong><span style=\"font-size:12.0pt\"> While this is a moderate risk, it&#39;s not high enough to warrant primary prophylaxis with G-CSF in the absence of other risk factors.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. She develops a fever and her absolute neutrophil count (ANC) drops to 500/&micro;L during her current treatment.</span></strong><span style=\"font-size:12.0pt\"> This scenario indicates the patient has already developed febrile neutropenia. G-CSF would be used for secondary prophylaxis in this case, not primary prophylaxis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. She is also scheduled to receive radiation therapy to her chest wall after completing chemotherapy.</span></strong><span style=\"font-size:12.0pt\"> Radiation therapy to the chest wall can sometimes cause a decrease in blood counts, but it&#39;s not a primary indication for G-CSF prophylaxis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational objective:</span></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A history of febrile neutropenia is a strong indication for G-CSF prophylaxis, even if the current chemotherapy regimen is not considered high-risk. This is because patients who have experienced febrile neutropenia in the past are at a significantly higher risk of developing it again with subsequent chemotherapy. </span></span><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Use if FN risk &ge; 20%, H/o Febrile Neutropenia, Neutropenia prior to starting chemo or active infection while starting chemo. </span></span></p>",
      "correct_choice_id": 79086,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19849,
      "choices": [
        {
          "id": 79357,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Mesna </span></span></span></p>"
        },
        {
          "id": 79358,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Dexamethasone </span></span></span></p>"
        },
        {
          "id": 79359,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ondansetron </span></span></span></p>"
        },
        {
          "id": 79360,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Allopurinol</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 55-year-old woman with breast cancer is undergoing adjuvant chemotherapy with cyclophosphamide. During her second cycle, she complains of burning sensation while urinating and notices blood in her urine. You suspect a complication due to chemotherapy. Which of the following medications is MOST likely to prevent this complication?</span></span></span></p>",
      "unique_key": "Q4316952",
      "question_audio": null,
      "question_video": null,
      "map_id": 16556513,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Mesna</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A.</span></strong></span></span></p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">&nbsp;Cyclophosphamide is metabolized to acrolein, a toxic compound that can damage the bladder lining, leading to hemorrhagic cystitis.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Mesna is a uroprotectant agent that specifically binds to acrolein in the bladder, neutralizing its toxic effects and preventing hemorrhagic cystitis.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Dexamethasone:</span></strong><span style=\"font-size:12.0pt\"> A corticosteroid used to manage nausea and vomiting associated with chemotherapy; it has no role in preventing hemorrhagic cystitis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Ondansetron:</span></strong><span style=\"font-size:12.0pt\"> A 5-HT3 receptor antagonist used to manage nausea and vomiting; it&#39;s not effective for preventing hemorrhagic cystitis</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Allopurinol:</span></strong><span style=\"font-size:12.0pt\"> A medication used to reduce uric acid levels, often in the context of tumor lysis syndrome; it has no role in preventing hemorrhagic cystitis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational objective:</span></strong> </span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Mesna is the standard preventive agent for hemorrhagic cystitis associated with cyclophosphamide. It should be administered concurrently with cyclophosphamide to minimize bladder toxicity.</span></span></span></p>",
      "correct_choice_id": 79357,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19850,
      "choices": [
        {
          "id": 79361,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cytarabine </span></span></span></p>"
        },
        {
          "id": 79362,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ifosfamide </span></span></span></p>"
        },
        {
          "id": 79363,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cisplatin </span></span></span></p>"
        },
        {
          "id": 79364,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Gemcitabine</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A patient receiving chemotherapy develops a &quot;glove and stocking&quot; pattern of numbness and tingling in their hands and feet. Which of the following drugs is MOST likely responsible?</span></span></span></p>",
      "unique_key": "Q7378733",
      "question_audio": null,
      "question_video": null,
      "map_id": 16556514,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Cisplatin</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The image explicitly states that platinum-based drugs like cisplatin are associated with glove and stocking neuropathy (a type of peripheral neuropathy affecting the hands and feet) and ototoxicity (hearing loss).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Cytarabine:</span></strong><span style=\"font-size:12.0pt\"> Cytarabine is primarily associated with cerebellar toxicity and myelosuppression. While it can rarely cause peripheral neuropathy, it is not typically characterized by a glove and stocking distribution.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Ifosfamide:</span></strong><span style=\"font-size:12.0pt\"> Ifosfamide can cause hemorrhagic cystitis and neurotoxicity, but the characteristic glove and stocking neuropathy is less common.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Gemcitabine:</span></strong><span style=\"font-size:12.0pt\"> Gemcitabine is associated with myelosuppression, flu-like symptoms, and rash. Peripheral neuropathy is not a typical side effect of this drug.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational objective:</span></strong> </span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Platinum-based chemotherapy agents carry the risk of peripheral neuropathy and ototoxicity.</span></span></span></p>",
      "correct_choice_id": 79363,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53420,
      "choices": [
        {
          "id": 213161,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Tumor lysis syndrome </span></span></span></p>"
        },
        {
          "id": 213162,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cytokine release syndrome (CRS) </span></span></span></p>"
        },
        {
          "id": 213163,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Graft-versus-host disease (GVHD) </span></span></span></p>"
        },
        {
          "id": 213164,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Sepsis</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A patient receiving CAR T-cell therapy develops fever, hypotension, and tachycardia two days after infusion. Which of the following is the MOST likely diagnosis?</span></span></span></p>",
      "unique_key": "Q5227100",
      "question_audio": null,
      "question_video": null,
      "map_id": 16556515,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Cytokine release syndrome (CRS)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The triad of fever, hypotension, and tachycardia shortly after CAR T-cell therapy is highly suggestive of CRS. This is due to the massive release of cytokines from activated T cells.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Tumor lysis syndrome:</span></strong><span style=\"font-size:12.0pt\"> While it can cause fever and electrolyte abnormalities, it&#39;s less likely to cause hypotension and tachycardia shortly after T-cell therapy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. GVHD:</span></strong><span style=\"font-size:12.0pt\"> This occurs in allogeneic stem cell transplantation, not CAR T-cell therapy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Sepsis:</span></strong><span style=\"font-size:12.0pt\"> Though sepsis can present similarly, the timing and context point more towards CRS in this scenario.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational objective:</span></strong> </span></span></p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">CRS is a serious complication of CAR T-cell therapy characterized by a systemic inflammatory response due to cytokine release.</span></span></p>",
      "correct_choice_id": 213162,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19837,
      "choices": [
        {
          "id": 79309,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Central diabetes insipidus </span></span></span></p>"
        },
        {
          "id": 79310,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Nephrogenic diabetes insipidus </span></span></span></p>"
        },
        {
          "id": 79311,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Syndrome of inappropriate antidiuretic hormone secretion (SIADH) </span></span></span></p>"
        },
        {
          "id": 79312,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Primary hyperaldosteronism</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 60-year-old man with a history of small cell lung cancer (SCLC) presents with confusion, lethargy, and muscle cramps. Laboratory findings reveal hyponatremia with a serum sodium level of 120 mEq/L, high urine sodium, and high urine osmolality. Which of the following is the MOST likely diagnosis?</span></span></p>",
      "unique_key": "Q1077488",
      "question_audio": null,
      "question_video": null,
      "map_id": 16556516,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Syndrome of inappropriate antidiuretic hormone secretion (SIADH)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient&#39;s presentation with hyponatremia, high urine sodium, and high urine osmolality, in the context of SCLC, is consistent with SIADH. SCLC is a known cause of SIADH due to ectopic production of vasopressin (ADH). The other options do not fit the clinical and laboratory picture.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Central diabetes insipidus:</span></strong><span style=\"font-size:12.0pt\"> This condition is caused by deficient production of ADH, leading to excessive water loss and hypernatremia (high serum sodium), not hyponatremia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Nephrogenic diabetes insipidus:</span></strong><span style=\"font-size:12.0pt\"> In this condition, the kidneys are unable to respond to ADH, also leading to excessive water loss and hypernatremia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Primary hyperaldosteronism:</span></strong><span style=\"font-size:12.0pt\"> This condition is characterized by excessive aldosterone production, leading to sodium retention, hypertension, and hypokalemia. It does not typically cause hyponatremia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">SIADH is characterized by hyponatremia with inappropriately concentrated urine due to excessive ADH secretion. SCLC is a common cause of SIADH.</span></span></p>",
      "correct_choice_id": 79311,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19839,
      "choices": [
        {
          "id": 79317,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Serum cortisol </span></span></span></p>"
        },
        {
          "id": 79318,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">24-hour urinary 5-HIAA </span></span></span></p>"
        },
        {
          "id": 79319,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Serum calcitonin </span></span></span></p>"
        },
        {
          "id": 79320,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Serum gastrin</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 45-year-old woman presents with recurrent episodes of flushing, accompanied by diarrhea and abdominal cramping. She has also noticed a rash on her face and neck that worsens during these episodes. On physical examination, you note telangiectasias on her cheeks and a palpable liver mass. Which of the following diagnostic tests is MOST likely to be elevated in this patient?</span></span></p>",
      "unique_key": "Q9966236",
      "question_audio": null,
      "question_video": null,
      "map_id": 16556517,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) 24-hour urinary 5-HIAA</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The combination of flushing, diarrhea, skin changes, and a palpable liver mass raises strong suspicion for carcinoid syndrome. Carcinoid tumors secrete vasoactive substances, primarily serotonin, leading to these characteristic symptoms. 24-hour urinary 5-HIAA (a metabolite of serotonin) is the most sensitive and specific test for diagnosing carcinoid syndrome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Serum cortisol:</span></strong><span style=\"font-size:12.0pt\"> Cortisol is elevated in Cushing&#39;s syndrome, which presents with different clinical features (central obesity, muscle weakness, hypertension).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Serum calcitonin:</span></strong><span style=\"font-size:12.0pt\"> Calcitonin is a marker for medullary thyroid carcinoma (MTC), which can also cause flushing but usually presents with a neck mass or thyroid nodules.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Serum gastrin:</span></strong><span style=\"font-size:12.0pt\"> Gastrin is elevated in gastrinomas (a type of neuroendocrine tumor), which primarily cause peptic ulcers and abdominal pain, not the classic carcinoid syndrome symptoms.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Carcinoid syndrome is caused by the release of vasoactive substances, mainly serotonin, from carcinoid tumors.</span></span></span></li>\r\n\t<li><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">24-hour urinary 5-HIAA is the diagnostic test of choice for carcinoid syndrome.</span></span></li>\r\n</ul>",
      "correct_choice_id": 79318,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53430,
      "choices": [
        {
          "id": 213201,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Primary hyperparathyroidism </span></span></span></p>"
        },
        {
          "id": 213202,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Vitamin D deficiency </span></span></span></p>"
        },
        {
          "id": 213203,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Mesenchymal tumor producing FGF23 </span></span></span></p>"
        },
        {
          "id": 213204,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Multiple myeloma</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 50-year-old man presents with persistent bone pain and muscle weakness for several months. He has a history of recurrent fractures. Laboratory findings show hypophosphatemia, normal serum calcium, and decreased 1,25-dihydroxyvitamin D levels. Imaging studies reveal multiple bone lesions. Which of the following is the MOST likely underlying cause of his condition?</span></span></p>",
      "unique_key": "Q9219581",
      "question_audio": null,
      "question_video": null,
      "map_id": 16556518,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C) Mesenchymal tumor producing FGF23</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The combination of bone pain, muscle weakness, recurrent fractures, hypophosphatemia, normal calcium, and decreased 1,25-dihydroxyvitamin D levels strongly suggests oncogenic osteomalacia. This rare paraneoplastic syndrome is caused by tumors that secrete fibroblast growth factor 23 (FGF23), leading to renal phosphate wasting and impaired vitamin D activation. The image lists hemangiopericytomas, fibromas, sarcomas, giant cell tumors, and osteoblastomas as potential culprits, along with prostate and lung cancers.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Primary hyperparathyroidism:</span></strong><span style=\"font-size:12.0pt\"> This would cause hypercalcemia, not hypophosphatemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Vitamin D deficiency:</span></strong><span style=\"font-size:12.0pt\"> This would also cause hypophosphatemia, but 1,25-dihydroxyvitamin D levels would be low or inappropriately normal, not decreased.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Multiple myeloma:</span></strong><span style=\"font-size:12.0pt\"> Myeloma can cause bone pain and fractures, but it typically presents with hypercalcemia and renal insufficiency.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Oncogenic osteomalacia is a rare paraneoplastic syndrome caused by tumors that secrete FGF23.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Recognizing the characteristic clinical and laboratory findings is crucial for prompt diagnosis and treatment.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Identifying and removing the underlying tumor can lead to resolution of the osteomalacia.</span></span></span></li>\r\n</ul>",
      "correct_choice_id": 213203,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19785,
      "choices": [
        {
          "id": 79101,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Angiography </span></span></span></p>"
        },
        {
          "id": 79102,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Apixaban </span></span></span></p>"
        },
        {
          "id": 79103,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Unfractionated heparin </span></span></span></p>"
        },
        {
          "id": 79104,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Venous duplex ultrasonography</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 75-year-old man with a history of atrial fibrillation, diabetes, and peripheral artery disease presents with acute left leg pain, absent pulses, and cold, mottled skin. What is the most appropriate next step?</span></span></p>",
      "unique_key": "Q4623786",
      "question_audio": null,
      "question_video": null,
      "map_id": 16556519,
      "difficulty_level": "difficult",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C) Unfractionated heparin</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">This patient presents with acute limb ischemia (ALI). Immediate anticoagulation with unfractionated heparin is crucial to prevent further thrombus propagation while awaiting definitive intervention (angiography).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Angiography</span></strong><span style=\"font-size:12.0pt\">: Essential for diagnosis and planning revascularization, but anticoagulation should be started first. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Apixaban</span></strong><span style=\"font-size:12.0pt\">: Oral anticoagulant, not appropriate in the acute setting of ALI. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Venous duplex ultrasonography</span></strong><span style=\"font-size:12.0pt\">: Not indicated for ALI, which is an arterial problem.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Treat acute limb ischemia with anticoagulation.</span></span></span></p>",
      "correct_choice_id": 79103,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19786,
      "choices": [
        {
          "id": 79105,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Amiodarone </span></span></span></p>"
        },
        {
          "id": 79106,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Exercise ECG </span></span></span></p>"
        },
        {
          "id": 79107,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Propranolol </span></span></span></p>"
        },
        {
          "id": 79108,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Reassurance</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 45-year-old woman with no medical history presents with frequent, bothersome palpitations that subside with exercise and in the nights. ECG is shown. Echo and baseline lab tests including CBC and TFT are normal. What is the most appropriate management?</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/20/screenshot-2024-08-20-172502.png\" style=\"height:138px; width:300px\" /></span></span></p>",
      "unique_key": "Q2886254",
      "question_audio": null,
      "question_video": null,
      "map_id": 16556520,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C) Propranolol</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient has symptomatic premature ventricular contractions (PVCs) that are bothersome. Beta-blockers are the first-line treatment for symptomatic PVCs.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Amiodarone</span></strong><span style=\"font-size:12.0pt\">: Antiarrhythmic drug with potential toxicity, not first-line for simple PVCs. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Exercise ECG</span></strong><span style=\"font-size:12.0pt\">: Not helpful for diagnosing PVCs.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Reassurance</span></strong><span style=\"font-size:12.0pt\">: Not sufficient for bothersome symptoms.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Beta-blockers are the first-line treatment for symptomatic PVCs in patients without structural heart disease.</span></span></span></p>",
      "correct_choice_id": 79107,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "ImageBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54145,
      "choices": [
        {
          "id": 216049,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Echocardiography </span></span></span></p>"
        },
        {
          "id": 216050,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Eplerenone </span></span></span></p>"
        },
        {
          "id": 216051,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Oxygen per nasal cannula </span></span></span></p>"
        },
        {
          "id": 216052,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Urgent coronary angiography</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 65-year-old man presents with recurrent chest pain and elevated troponin. ECG is shown. remains in pain despite aspirin, clopidogrel, heparin, and nitroglycerin. What is the most appropriate management?</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/20/screenshot-2024-08-20-173300.png\" style=\"height:256px; width:300px\" /></span></span></p>",
      "unique_key": "Q9684555",
      "question_audio": null,
      "question_video": null,
      "map_id": 16556521,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>D) Urgent coronary angiography</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">This patient has NSTE-ACS with refractory angina despite medical therapy. Urgent coronary angiography is indicated to identify the culprit lesion and potentially perform revascularization.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Echocardiography</span></strong><span style=\"font-size:12.0pt\">: May be helpful, but not the immediate priority. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Eplerenone</span></strong><span style=\"font-size:12.0pt\">: Indicated in certain post-MI patients, but not the immediate priority for refractory angina. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Oxygen per nasal cannula</span></strong><span style=\"font-size:12.0pt\">: Indicated only if the patient is hypoxic.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Urgent or immediate diagnostic angiography with intent to perform revascularization is indicated in patients with NSTE-ACS who have refractory angina or hemodynamic or electrical instability.</span></span></span></p>",
      "correct_choice_id": 216052,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "ImageBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54147,
      "choices": [
        {
          "id": 216057,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Clopidogrel </span></span></span></p>"
        },
        {
          "id": 216058,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Liraglutide</span></span></span></p>"
        },
        {
          "id": 216059,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Niacin </span></span></span></p>"
        },
        {
          "id": 216060,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pramlintide</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 68-year-old man with type 2 diabetes, hypertension, hyperlipidemia, and aortofemoral bypass surgery 2 years ago has an HbA1c of 7.1%. His current medications are metformin, atenolol, ramipril, amlodipine, aspirin, rivaroxaban, and atorvastatin. Which medication is most appropriate to add for cardiovascular risk reduction?</span></span></p>",
      "unique_key": "Q8365159",
      "question_audio": null,
      "question_video": null,
      "map_id": 16556522,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>B) Liraglutide</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">GLP-1 receptor agonists like liraglutide have been shown to reduce cardiovascular events in patients with type 2 diabetes and established atherosclerotic cardiovascular disease (ASCVD), which this patient has due to his history of bypass surgery. Liraglutide also promotes weight loss, which can be beneficial for this patient. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Clopidogrel</span></strong><span style=\"font-size:12.0pt\">: Patient is already on rivaroxaban and aspirin. Addition of clopidogrel would not provide any additional benefit and only increase the bleeding risk. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Niacin</span></strong><span style=\"font-size:12.0pt\">: No longer recommended for routine use due to lack of benefit and side effects. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Pramlintide</span></strong><span style=\"font-size:12.0pt\">: Amylin analog used for glycemic control, no proven cardiovascular benefit.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">In patients with type 2 diabetes mellitus, sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists are associated with reduced rates of adverse cardiovascular events, including stroke, myocardial infarction, and cardiovascular death, compared with placebo.</span></span></span></p>",
      "correct_choice_id": 216058,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54149,
      "choices": [
        {
          "id": 216065,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Empagliflozin</span></span></span></p>"
        },
        {
          "id": 216066,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ezetimibe </span></span></span></p>"
        },
        {
          "id": 216067,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Niacin</span></span></span></p>"
        },
        {
          "id": 216068,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">No changes in management</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 59-year-old man with type 2 diabetes and a history of stroke is on aspirin, metformin, olmesartan, and rosuvastatin. His LDL-C is 66 mg/dL, HDL-C is 28 mg/dL and HbA1c is 6.8%. What additional medication should be considered for CV risk reduction?</span></span></p>",
      "unique_key": "Q1218758",
      "question_audio": null,
      "question_video": null,
      "map_id": 16556523,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>A) Empagliflozin</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">SGLT2 inhibitors like empagliflozin have been shown to reduce cardiovascular events in patients with type 2 diabetes and established ASCVD. They are recommended as part of a comprehensive cardiovascular risk reduction strategy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Ezetimibe</span></strong><span style=\"font-size:12.0pt\">: Not indicated as LDL cholesterol is already well-controlled. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Niacin</span></strong><span style=\"font-size:12.0pt\">: Can increase HDL but no longer recommended for routine use due to lack of benefit and side effects.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. No changes in management</span></strong><span style=\"font-size:12.0pt\">: Inadequate as SGLT2 inhibitors provide additional CV benefit.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Consider adding SGLT2 inhibitors to the treatment regimen for patients with type 2 diabetes and established ASCVD to reduce CV risk.</span></span></span></p>",
      "correct_choice_id": 216065,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20081,
      "choices": [
        {
          "id": 80285,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Check ketones </span></span></span></p>"
        },
        {
          "id": 80286,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Inject insulin and exercise </span></span></span></p>"
        },
        {
          "id": 80287,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Avoid carbohydrates for the day </span></span></span></p>"
        },
        {
          "id": 80288,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Recheck CBG the next day</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 21-year-old professional gym trainer who is a known type 1 diabetic is about to start a training session. Just before the session, he notices his capillary blood glucose (CBG) to be 280 mg/dL. What should he do?</span></span></p>",
      "unique_key": "Q8787013",
      "question_audio": null,
      "question_video": null,
      "map_id": 16556524,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Check ketones</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A CBG of 280 mg/dL indicates significant hyperglycemia, which can be dangerous for people with type 1 diabetes. Before exercising, it is essential to check for ketones. The presence of ketones indicates that the body is breaking down fat for energy due to insufficient insulin, and this can lead to diabetic ketoacidosis (DKA), a serious condition. If ketones are present, the individual should not exercise and seek medical attention immediately.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Glycemic management during exercise:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">CBG &lt; 90 mg/dL:</span></strong><span style=\"font-size:12.0pt\"> Ingest 15 to 30&thinsp;g of glucose before starting exercise. Delay exercise until blood glucose is&nbsp;90&thinsp;mg/dL and monitor closely for hypoglycaemia.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">CBG 90 to 125 mg/dL:</span></strong><span style=\"font-size:12.0pt\"> Ingest 10&thinsp;g of glucose before starting aerobic exercise. Anaerobic exercise and high intensity interval training sessions can be started.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">CBG 126 to 250 mg/dL:</span></strong><span style=\"font-size:12.0pt\"> Aerobic exercise can be started. </span></span></span></li>\r\n</ul>\r\n\r\n<ul style=\"list-style-type:circle; margin-left:40px\">\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Anaerobic exercise can be started, but glucose concentrations could rise.</span></span></span></li>\r\n</ul>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">CBG &gt; 250 mg/dL</span></strong><span style=\"font-size:12.0pt\">: Check ketones. </span></span></span></li>\r\n</ul>\r\n\r\n<ul style=\"list-style-type:circle; margin-left:40px\">\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ketones &lt; 0&middot;6&thinsp;mmol/L: Mild-to-moderate aerobic exercise can be started</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ketones 0.6- 1&middot;4&thinsp;mmol/L: Exercise should be restricted to a light intensity for only a brief duration (&lt;30&thinsp;min) and a small corrective insulin dose might be needed. </span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ketones &ge;1.5&thinsp;mmol/L: Exercise is contraindicated and glucose management should be initiated rapidly as per the advice of the healthcare professional team.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Inject insulin and exercise:</span></strong><span style=\"font-size:12.0pt\"> Injecting insulin before exercise could lead to hypoglycemia during the workout, which can be dangerous.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Avoid carbohydrates for the day:</span></strong><span style=\"font-size:12.0pt\"> This could also lead to hypoglycemia as carbohydrates are the primary source of energy for the body.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Recheck CBG the next day:</span></strong><span style=\"font-size:12.0pt\"> Delaying action on elevated blood sugar levels is not recommended and could lead to complications.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Check for ketones before exercising if blood glucose levels are above 250 mg/dL to prevent the risk of diabetic ketoacidosis.</span></span></span></p>",
      "correct_choice_id": 80285,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20089,
      "choices": [
        {
          "id": 80317,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Metformin </span></span></span></p>"
        },
        {
          "id": 80318,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Canagliflozin </span></span></span></p>"
        },
        {
          "id": 80319,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Semaglutide </span></span></span></p>"
        },
        {
          "id": 80320,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pioglitazone</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 45-year-old woman with type 2 diabetes on insulin was recently started on a new drug. After a week, she presents with nausea, vomiting, abdominal pain, near-normal blood glucose, elevated anion gap metabolic acidosis, and elevated plasma ketones. Which of the following medications is the most likely cause?</span></span></p>",
      "unique_key": "Q7706261",
      "question_audio": null,
      "question_video": null,
      "map_id": 16556525,
      "difficulty_level": "difficult",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Canagliflozin</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient&#39;s presentation is consistent with euglycemic diabetic ketoacidosis (euDKA), a rare but serious complication of diabetes. While DKA is typically associated with high blood glucose levels, euDKA occurs with near-normal or even low blood glucose.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Canagliflozin, an SGLT2 inhibitor, is known to increase the risk of euDKA. It works by increasing urinary glucose excretion, which can lead to a relative deficit of glucose available for energy. This can trigger the body to break down fat for fuel, producing ketones and leading to acidosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Metformin:</span></strong><span style=\"font-size:12.0pt\"> Metformin can rarely cause lactic acidosis but not associated with euDKA. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Semaglutide:</span></strong><span style=\"font-size:12.0pt\"> Semaglutide (a GLP-1 receptor agonist) is not associated with euDKA.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Pioglitazone:</span></strong><span style=\"font-size:12.0pt\"> Pioglitazone (a thiazolidinedione) is not known to cause euDKA.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Canagliflozin, an SGLT2 inhibitor, can cause euglycemic diabetic ketoacidosis (euDKA).</span></span></span></p>",
      "correct_choice_id": 80318,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20091,
      "choices": [
        {
          "id": 80325,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Liraglutide </span></span></span></p>"
        },
        {
          "id": 80326,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Dulaglutide </span></span></span></p>"
        },
        {
          "id": 80327,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Semaglutide </span></span></span></p>"
        },
        {
          "id": 80328,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Tirzepatide</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 55-year-old woman with type 2 diabetes mellitus and obesity presents to the clinic. She is currently taking metformin 1000 mg twice daily, but her glycemic control remains suboptimal (HbA1c 8.5%). She is interested in a medication that can help with both weight loss and glucose control. Which of the following medications would be most appropriate for this patient?</span></span></p>",
      "unique_key": "Q1225117",
      "question_audio": null,
      "question_video": null,
      "map_id": 16556526,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Tirzepatide</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, making it a suitable option for patients with type 2 diabetes who need both improved glycemic control and weight loss. It has been shown to be more effective than other GLP-1 receptor agonists in achieving these goals.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Liraglutide, Option B. Dulaglutide&nbsp;</span></strong><span style=\"font-size:12.0pt\">and </span><strong><span style=\"font-size:12.0pt\">Option C. Semaglutide:</span></strong><span style=\"font-size:12.0pt\"> While these GLP-1 receptor agonists can promote weight loss and improve glycemic control, tirzepatide has shown superior efficacy in clinical trials compared to these options.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Tirzepatide, a dual GIP and GLP-1 receptor agonist, is highly effective for both glycemic control and weight loss in type 2 diabetes.</span></span></span></p>",
      "correct_choice_id": 80328,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}